Neuroendocrine Tumors

TOPIC-NEC trial

In the randomized phase III TOPIC-NEC trial, Etoposide and cisplatin (EP) showed comparable efficacy to irinotecan and cisplatin (IE) as...

Lung Cancer Bladder Cancer Breast Cancer CNS Cancers Colorectal Cancer COVID-19 Gastroesophageal Cancer Gastrointestinal Cancer Genomics/Genetics Geriatric Oncology Gynecologic Cancers Head and Neck Cancers Health-Care Policy Hepatobiliary Cancer Immunotherapy Integrative Oncology Kidney Cancer Legislation Leukemia Lymphoma Multiple Myeloma Neuroendocrine Tumors Palliative Care Pancreatic Cancer Prostate Cancer Sarcoma Skin Cancer Survivorship Symptom management Thyroid Cancer

FDA approval of bevacizumab biosimilar

On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...

Clinical trials summary

Expert Interviews

Oncology Watch Discussions